The focus of our lab is to study how inflammation, via modulating cellular metabolism, affects different aspects of cancer biology. In particular, we are interested in understating how obesity-associated inflammation rewires cellular metabolism, increasing the risk of breast cancer in obese women.
Our group studies changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
My lab aims to understand the alterations in metabolism that take place in cancer and investigate whether extrinsic factors, such as diet, influence cancer metabolism and disease trajectory. We then want to uncover whether these dependencies can be exploited therapeutically.
My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
My main research interest is in exploring why ASS1 is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy. I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers.
My research is focused on studying changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
In 2015 I was awarded a research associate position funded by Cancer Research UK to join Dr Sanz-Moreno for my postdoc, where I develop my research studying the crosstalk between the cytoskeleton and mitochondria during tumour progression and invasion.
My research is focused on the role of lipid metabolism in resistance to therapy in acute myeloid leukemia.
My areas of interest are imaging biochemical processes such as metabolism/proliferation (microPET), and the use of in vivo preclinical imaging in a range of applications.
My research looks at if/how invasive traits and metabolism of amoeboid versus mesenchymal cancer cells are altered in response to tissue mechanics, with the aim of developing anti-metastasis treatment(s).
My research projects involve identifying tumour suppressors involved in regulating the hypoxic response and metabolic stress, with the aim to identify novel targeted therapies against these.
Our research is focused on metabolic stresses accompanying activation of oncogenes. We are investigating cell responses to metabolic stresses in order to deeply understand these mechanisms and propose metabolic targets for cancer therapies.
We are interested in metabolic dependencies of B-cell lymphomas, in particular the serine synthesis pathway and one carbon metabolism.
My project looks at the metabolic mechanisms of drug resistance in acute myeloid leukaemia (AML). We look to understand what makes certain cells more vulnerable to AML treatment and how we can use this to improve overall treatment strategies.